WO2012105551A1 - 生理活性物質含有水溶化製剤、及びその製法 - Google Patents
生理活性物質含有水溶化製剤、及びその製法 Download PDFInfo
- Publication number
- WO2012105551A1 WO2012105551A1 PCT/JP2012/052133 JP2012052133W WO2012105551A1 WO 2012105551 A1 WO2012105551 A1 WO 2012105551A1 JP 2012052133 W JP2012052133 W JP 2012052133W WO 2012105551 A1 WO2012105551 A1 WO 2012105551A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- water
- active substance
- physiologically active
- weight
- soluble preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Definitions
- the present invention relates to a water-soluble preparation containing a physiologically active substance that can be used in foods and drinks such as health foods and health functional foods (food for specified health use, nutritional functional foods), pharmaceuticals, quasi drugs, cosmetics, etc. And its manufacturing method.
- a licorice hydrophobic component extracted from a licorice or licorice water extraction residue with an organic solvent or the like has many useful properties such as an antioxidant action, an antibacterial action, an enzyme inhibitory action, an antitumor action, an antiallergic action, and an antiviral action. It has been confirmed to show an action.
- this licorice hydrophobic component does not dissolve in water and is difficult to add to water-based foods as it is, but also hardly dissolves in general oils, and further solidifies as an organic solvent extract. It may be difficult to use because it may be unstable, such as coloring easily.
- Patent Document 1 uses a method of mixing an oil-based solvent containing 10% or more of an oil-soluble polyhydric alcohol fatty acid ester with a licorice hydrophobic extract.
- the licorice hydrophobic component-containing oil / fat composition cannot be solubilized in an aqueous object or the like as it is.
- Patent Document 2 discloses that a licorice hydrophobic flavonoid and a medium-chain fatty acid triglyceride dissolved in an oil-in-water emulsion in the presence of an emulsifier are intended for simple water dispersibility. However, transparency and acid resistance are not intended.
- Patent Document 3 proposes a composition containing a licorice oily extract and a polyglycerin laurate, but the acid resistance and heat resistance required when added to a beverage are not sufficient.
- Patent Document 4 discloses a licorice polyphenol-containing oil-in-water emulsion composition containing a polyglycerin fatty acid ester composed of a fatty acid residue having 14 or more carbon atoms. Homogenization treatment under high pressure conditions is required.
- Patent Document 5 discloses an oil-and-fat solubilized composition using polyglycerin having an average degree of polymerization of 6 to 10 and a monoester of saturated fatty acid having 12 to 14 carbon atoms. Homogenization treatment is necessary.
- Patent Document 6 discloses an oil-soluble substance-solubilized composition using polyglycerin having an average degree of polymerization of 5 to 10 and a monoester of myristic acid or oleic acid. Homogenization treatment is required.
- Patent Document 7 discloses a self-emulsifying preparation using a polyoxyethylene sorbitan fatty acid ester, and is said to form a microemulsion by contacting an aqueous medium.
- polyoxyethylene sorbitan fatty acid esters are severely restricted in food use and cannot be widely applied to food.
- Patent Document 8 discloses a stable aqueous composition in which an oil-soluble substance is solubilized or dispersed in an aqueous medium with a special polyglycerin saturated fatty acid ester having a cloud point of 20 ° C. or higher.
- the conventional technology lacks dispersibility and transparency when used for water-based objects, and is insufficient in heat resistance and acid resistance particularly required for drinks and the like. There are limits to its application, such as the need to use special surfactants. Furthermore, in the production of an oil-in-water emulsion composition using a polyglycerin fatty acid ester, there is a problem that in general, high-pressure treatment is often required and the process is complicated.
- the present invention is to provide a water-solubilized preparation obtained by a simple process, and even if the water-solubilized preparation is added to an aqueous object, the original properties of the object are not impaired. The task is to maintain stability.
- the inventors of the present invention can easily prepare a stable water-soluble preparation by combining specific surfactants having different HLB (Hydrophile-Lipophile Balance) values.
- the water-soluble preparation was also found to be a self-emulsifying preparation that forms a microemulsion simply by contacting an aqueous medium, and the present invention has been completed.
- the present invention comprises 1 to 50% by weight of an oily component (A) containing a physiologically active substance and fats and oils, 10 to 98% by weight of a polyglycerol fatty acid ester (B) having an HLB value of 12.5 or more, and HLB.
- the present invention relates to a water-soluble preparation containing a physiologically active substance containing 1 to 40% by weight of a surfactant (C) having a value of 7 to 11.8.
- the present invention provides an oily component (A) containing a physiologically active substance and fats and oils in an amount of 1 to 50% by weight, a polyglycerol fatty acid ester (B) having an HLB value of 12.5 or more, and 10 to 98% by weight.
- a bioactive substance-containing water-soluble preparation containing 1 to 40% by weight of a surfactant (C) having a value of 7 to 11.8 is added to an aqueous medium (aqueous solvent) such as water or an aqueous solution, followed by heat treatment and / or
- the present invention also relates to a method for producing a physiologically active substance-solubilized aqueous solution characterized by acid treatment.
- the water-soluble preparation containing a physiologically active substance of the present invention a high-concentration and stable water-soluble preparation for water-solubilizing a fat-soluble physiologically active substance is produced without requiring a complicated process such as high-pressure treatment. Can do.
- the physiologically active substance-containing water-soluble preparation of the present invention can easily diffuse into an aqueous medium to form a microemulsion excellent in acid resistance and heat resistance, and the obtained microemulsion has high storage stability.
- the aqueous emulsified solution obtained by the water-soluble preparation containing the physiologically active substance of the present invention is excellent in acid resistance and heat resistance, and can be applied to various uses.
- the physiologically active substance-containing water-soluble preparation of the present invention (hereinafter also simply referred to as “the water-soluble preparation of the present invention”) has an oily component (A) containing a physiologically active substance and an oil and fat in an amount of 1 to 50% by weight and an HLB value.
- a preparation comprising 10 to 98% by weight of a polyglycerol fatty acid ester (B) of 12.5 or more and 1 to 40% by weight of a surfactant (C) having an HLB value of 7 to 11.8. .
- the physiologically active substance used in the oil-based component (A) of the water-solubilized preparation of the present invention is not particularly limited as long as it is a fat-soluble or sparingly water-soluble substance having physiological activity, but preferably a plant extract or a fat-soluble substance. Vitamins, carotenoids and the like can be mentioned.
- the plant extract is not particularly limited, and a hydrophobic plant extract obtained by extraction from a plant generally used for food using an organic solvent can be used.
- a hydrophobic plant extract obtained by extraction from a plant generally used for food using an organic solvent can be used.
- licorice, chrysanthemum flower, turmeric, perilla, clove, cinnamon, ginger, lemongrass, peppermint, dokudami, yokuinin, rice bran, cornflower, fennel, wolfberry, salamander, nasturtium, san yak, sanyo, kinkaran, amacha eel, sakuhakuyou, hakutou Plants such as parsley, onion, nutmeg, wild rice, gluten feed, konjac flying powder, paprika, horseradish, lemon, chili, sesame, spearmint, marigold, haematococcus algae and high vegetable, etc.
- a hydrophobic extract obtained by extraction using an organic solvent such as ethanol, acetone, hexane, etc. contains, for example, polyphenols, terpenes and the like as active ingredients.
- a preferred plant extract is an extract of licorice or chrysanthemum, preferably a hydrophobic extract of licorice or chrysanthemum, more preferably an extract obtained by extracting licorice or chrysanthemum with ethanol, that is, licorice ethanol extraction.
- the fat-soluble vitamins are not particularly limited, and vitamin A, vitamin D, vitamin E such as tocophenol and tocotrienol, vitamin K, coenzyme Q such as oxidized coenzyme Q10 and reduced coenzyme Q10, and their Derivatives and the like. Of course, a mixture thereof may be used.
- the carotenoids are not particularly limited, and examples include carotenes, xanthophylls, and derivatives thereof.
- carotenes include ⁇ -carotene, ⁇ -carotene, ⁇ -carotene, ⁇ -carotene, and lycopene.
- xanthophylls include lutein, zeaxanthin, canthaxanthin, fucoxanthin, anthaxanthin, violaxanthin, astaxanthin, and the like. Is preferred.
- the oil component (A) a mixture of the above physiologically active substance and oil is used as the oil component (A).
- the mixture of the physiologically active substance and the fat is mixed visually and uniformly.
- the fats and oils used in the oil component (A) are not particularly limited, and may be, for example, natural fats and oils from animals and plants, or synthetic fats and processed fats and oils. More preferably, it is acceptable for food, cosmetics or medicine. Specifically, for example, palm oil, palm oil, palm kernel oil, linseed oil, camellia oil, brown rice germ oil, rapeseed oil, rice oil, peanut oil, corn oil, wheat germ oil, soybean oil, egoma oil, cottonseed oil, Sunflower seed oil, kapok oil, evening primrose oil, shea fat, monkey fat, cocoa butter, sesame oil, safflower oil, olive oil, pomegranate oil, bitter gourd oil, etc.
- MCT medium chain fatty acid triglycerides
- oils and fats processed by fractionation, hydrogenation, transesterification, etc. for example, hardened oils
- examples include partial glycerides. Needless to say, a mixture of these may be used.
- medium chain fatty acid triglycerides are most preferable from the viewpoints of ease of handling, oxidation stability and the like in addition to efficient dissolution of the plant extract.
- the mixing ratio of the physiologically active substance and fat / oil in the oily component (A) is appropriately selected depending on the nature of the physiologically active substance and the type of fat / oil used.
- the composition of the oil component (A) is licorice ethanol extract or chrysanthemum ethanol extract.
- 10 to 50% by weight of the medium chain fatty acid triglyceride is preferably 50 to 90% by weight, and the licorice ethanol extract or chrysanthemum ethanol extract is 20 to 40% by weight and the medium chain fatty acid triglyceride is A ratio of 60 to 80% by weight is more preferable.
- the content of the oily component (A) containing the physiologically active substance in the physiologically active substance-containing water-soluble preparation is not particularly limited as long as it is in the range of 1 to 50% by weight. It is preferably in the range of ⁇ 40% by weight, more preferably in the range of 5-30% by weight, and most preferably in the range of 10-30% by weight.
- the content of the oil component (A) in the water-soluble preparation of the present invention is less than 1% by weight, it is necessary to ingest a large amount of the preparation when orally administering a predetermined amount of the physiologically active substance, On the other hand, when the content of the oil component (A) in the preparation is 50% by weight or more, the stability when added to an aqueous medium becomes insufficient.
- the polyglycerin fatty acid ester (B) used in the water-solubilized preparation of the present invention is not particularly limited as long as it is a polyglycerin fatty acid ester having an HLB value of 12.5 or more, but a polyglycerin having an average polymerization degree of glycerin of 6 or more. Glycerin fatty acid esters are preferred, polyglycerin fatty acid esters having an average degree of polymerization of 6 to 10 are more preferred, and decaglycerin fatty acid esters having an average degree of polymerization of 10 are more preferred.
- the constituent fatty acid of the polyglycerol fatty acid ester (B) is not particularly limited, but is preferably a fatty acid having 8 to 20 carbon atoms, more preferably a fatty acid having 10 to 18 carbon atoms, and further a fatty acid having 12 to 16 carbon atoms. Preferable are fatty acids having 12 or 14 carbon atoms, that is, lauric acid or myristic acid.
- the polyglycerol fatty acid ester (B) may be a monoester or a polyester, but is preferably a monoester or a diester, and more preferably a polyglycerol monofatty acid ester that is a monoester.
- decaglycerol monolaurate decaglycerol monomyristate, decaglycerol monostearate, decaglycerol monooleate, decaglycerol monocaprylate, etc.
- decaglycerin monolaurate or decaglycerin monomyristate is particularly preferable.
- the content of the polyglycerin fatty acid ester (B) having an HLB value of 12.5 or more in the water-soluble preparation is not particularly limited as long as it is in the range of 10 to 98% by weight.
- the range is preferably from 35 to 98% by weight, more preferably from 60 to 92% by weight, and most preferably from 60 to 85% by weight.
- the content of the polyglycerin fatty acid ester (B) in the water-soluble preparation of the present invention is less than 10% by weight, each component in the preparation is separated without being uniformly diffused, and is more than 98% by weight. Is insufficiently stable when added to an aqueous medium.
- the surfactant (C) used in the water-solubilized preparation of the present invention is not particularly limited as long as it is a surfactant having an HLB value of 7 to 11.8.
- Polyglycerin fatty acid ester, sucrose fatty acid ester, sorbitan Fatty acid esters, polyoxyethylene sorbitan fatty acid esters, lecithins and the like can be used. Among these, polyglycerol fatty acid esters are preferable, and polyglycerol fatty acid esters having an average degree of polymerization of glycerol of 2 to 6 are more preferable.
- the constituent fatty acid in the case of using polyglycerin fatty acid ester as the surfactant (C) is not particularly limited, and a fatty acid having 6 to 22 carbon atoms can be normally selected, but a fatty acid having 10 to 18 carbon atoms is preferable, and Is more preferably 12-18, more preferably oleic acid or stearic acid, most preferably oleic acid.
- the surfactant (C) diglycerol monooleate, diglycerol monostearate, triglycerol monooleate, triglycerol monostearate, tetraglycerol monolaurate, tetraglycerol mono Oleic acid ester, tetraglycerin monostearic acid ester, pentaglycerin monooleic acid ester, pentaglycerin dioleic acid ester, pentaglycerin trioleic acid ester, pentaglycerin monostearic acid ester, pentaglycerin distearic acid ester, pentaglycerin tristearic acid Esters, hexaglycerin monooleate, hexaglycerin dioleate, hexaglycerin trioleate , Hexaglycerin tetraoleate, hexaglycerin monostearate, hexaglyceryl distearate, hexagly
- the content of the surfactant (C) having an HLB value of 7 to 11.8 in the water-soluble preparation is not particularly limited as long as it is in the range of 1 to 40% by weight.
- the range is preferably 1 to 25% by weight, more preferably 3 to 10% by weight, and most preferably 5 to 10% by weight.
- the content of the surfactant (C) in the water-solubilized preparation is less than 1% by weight, the stability when added to an aqueous medium is insufficient, and when it is more than 40% by weight, Each component does not diffuse uniformly and is separated.
- the water-solubilized preparation of the present invention comprises an oily component (A) containing the above physiologically active substance and oil, a polyglycerin fatty acid ester (B) having an HLB value of 12.5 or more, and a surface activity having an HLB value of 7 to 11.8. It can be easily prepared only by mixing the agent (C) uniformly. Specifically, each component heated as necessary may be simply mechanically or manually mixed, and can be produced without requiring a special stirring device for mixing. That is, the production of the water-soluble preparation of the present invention does not require an emulsifier that gives a strong shearing force or a pressure emulsifier such as a high-pressure homogenizer. Of course, these may be used.
- the pressure range during mixing is not particularly limited. However, since high-pressure emulsification is not required in the present invention, 100 kgf / cm 2 (about 10 MPa) or less is usually sufficient, and of course, no pressure is applied ( That is, it can be carried out at normal pressure (about 0.1 MPa).
- a desired physiologically active substance containing water-soluble formulation can be prepared even if it implements with what addition order and addition method. .
- the step of preparing the water-solubilized preparation of the present invention is preferably performed under a temperature condition that can secure a certain degree of fluidity of each component added from the viewpoint of production efficiency. It is carried out in the range of 50 to 80 ° C.
- an oily component (A) containing a physiologically active substance and fat during mixing a polyglycerin fatty acid ester (B) having an HLB value of 12.5 or more.
- Water and / or alcohols may be added as components other than the surfactant (C) having an HLB value of 7 to 11.8.
- the content of water and / or alcohol that can be added to the water-solubilized preparation of the present invention is not particularly limited, but the upper limit is preferably 12% by weight or less, more preferably 10% by weight or less. It is preferably 8% by weight or less.
- the stability of the physiologically active substance-solubilized aqueous solution obtained by adding the water-solubilized preparation of the present invention to an aqueous medium tends to be reduced.
- the lower limit of the content of water and / or alcohol in the water-soluble preparation of the present invention is not particularly limited. Since the water-soluble preparation of the present invention does not necessarily require water and / or alcohol, its lower limit is 0% by weight. However, when added, it is usually 1 for the purpose of improving fluidity and reducing viscosity. % By weight or more, preferably 2% by weight or more, more preferably 3% by weight or more.
- the water to add is not specifically limited, For example, distilled water, deionized water, drinking water etc. can be used.
- the alcohols to be added are not particularly limited, but ethanol can be preferably used in that a subsequent removal step is not necessarily required.
- addition of ethanol may be preferable also from the point which improves the characteristic of the water-soluble preparation obtained as mentioned later.
- the added alcohol is present in the water-soluble preparation due to the type or purpose of use of the preparation, after the mixing step, the alcohol is partially distilled off to an allowable amount by vacuum concentration or the like. Or can be completely removed.
- the water-solubilized preparation of the present invention has good solubility in water
- a physiologically active substance-solubilized aqueous solution in which a physiologically active substance is solubilized can be easily prepared by mixing with an aqueous medium.
- the water-soluble preparation has particularly good solubility in an aqueous solvent and has high transparency.
- An active substance-solubilized aqueous solution can be prepared.
- the physiologically active substance-solubilized aqueous solution mentioned here includes oil-in-water emulsion compositions such as microemulsions and nanoemulsions.
- the water-soluble preparation of the present invention requires the oil component (A), a polyglycerol fatty acid ester (B) having an HLB value of 12.5 or more, and a surfactant (C) having an HLB value of 7 to 11.8.
- oil component (A) a polyglycerol fatty acid ester having an HLB value of 12.5 or more
- C a surfactant having an HLB value of 7 to 11.8.
- pigments, anti-aggregation agents, absorption promoters, thickeners, thickening polysaccharides and other stabilizers, solubilizers, pH adjusters, antioxidants Agents, fragrances and the like can be included and are not particularly limited.
- aqueous medium that can be mixed with the water-soluble preparation of the present invention
- water itself or an aqueous solution in which water-soluble components are dissolved in water is preferably used.
- the physiologically active substance solubilized aqueous solution in which the water-soluble preparation of the present invention is dissolved in water is not included in the aqueous solution here.
- Water-soluble components that can be dissolved in an aqueous medium are not particularly limited, but water-soluble vitamins such as vitamin C, organic acids such as citric acid, acetic acid, malic acid, amino acids, peptides, L-carnitine, various salts, Examples include caffeine, fruit juice, milk components, tea extract, coffee extract and the like.
- a polyhydric alcohol may be sufficient.
- the polyhydric alcohol include saccharides such as monosaccharides, disaccharides, oligosaccharides, and liquid sugars, and sugar alcohols such as glycerin and sorbitol. Any of these water-soluble components can be added to the aqueous medium as long as it does not affect the emulsification.
- the upper limit of the amount of the physiologically active substance-containing water-solubilized preparation when the physiologically active substance-solubilized aqueous solution is prepared using the water-solubilized preparation of the present invention is not particularly limited.
- the water-solubilized preparation of the present invention is usually mixed in an amount of 20 g or less, preferably 10 g or less, more preferably 5 g or less with respect to 100 mL of an aqueous medium such as water or an aqueous solution. If the amount of the water-soluble preparation of the present invention is 20 g or more, the physiologically active substance-containing water-soluble preparation may not be uniformly diffused, resulting in poor handling properties.
- the lower limit of the addition amount of the water-solubilized preparation of the present invention is not particularly limited, but from the viewpoint of the effective amount of the physiologically active substance contained in the obtained physiologically active substance-solubilized aqueous solution, it is usually based on 100 mL of aqueous medium such as water Then, 10 mg or more, preferably 30 mg or more, more preferably 50 mg or more of the water-soluble preparation of the present invention is mixed.
- a magnetic stirrer, a propeller-type stirrer, an axial-flow turbine-type stirrer is usually used when uniformly mixed in an aqueous medium such as water or an aqueous solution. It can be easily dissolved and emulsified simply by stirring with an impeller stirrer such as a radial flow turbine stirrer or an anchor stirrer.
- an impeller stirrer such as a radial flow turbine stirrer or an anchor stirrer.
- it is not necessary to use a known emulsifying device such as a stirring homomixer or a high-pressure homogenizer.
- these high-pressure emulsification and homogenization treatments may be performed.
- the physiologically active substance solubilized aqueous solution prepared using the water-solubilized preparation of the present invention has excellent heat resistance and acid resistance, and is suitable for applications requiring acid resistance and heat resistance, such as drinks. ing. Furthermore, even when transparency and dispersibility are insufficient, dispersibility and transparency can be improved by performing heat treatment or acid treatment, particularly heat treatment. From such a viewpoint, the oily component (A) containing a physiologically active substance and fats and oils is 1 to 50% by weight, the polyglycerin fatty acid ester (B) having an HLB value of 12.5 or more is 10 to 98% by weight, and the HLB value.
- a bioactive substance-containing water-soluble preparation containing 1 to 40% by weight of a surfactant (C) having a weight of 7 to 11.8 is added to water or an aqueous solution, followed by heat treatment and / or acid treatment.
- the method for producing a physiologically active substance-solubilized aqueous solution is also an embodiment of the present invention.
- the conditions such as the heating temperature when performing the heat treatment are not particularly limited.
- the mixture is usually 80 ° C. or higher, preferably 85 ° C. or higher, more preferably Dispersibility and transparency are improved by heating to 90 ° C or higher.
- the acidity in the case of performing an acid treatment it is usually pH 5.0 or less, preferably pH 4.0 or less, more preferably pH 3.0 or less.
- a method for adjusting the acidity there is usually a method for adjusting a physiologically active substance solubilized aqueous solution obtained by adding an acidic substance to a mixture of the water-soluble preparation of the present invention and an aqueous medium to a predetermined pH. It is common.
- the acidic substance to be added must be selected according to the use application of the physiologically active substance solubilized aqueous solution. For example, acidic substances (acetic acid, malic acid, ascorbic acid, citric acid, sorbic acid, which are recognized as food additives for beverage applications) , Carbon dioxide, etc.).
- the physiologically active substance-containing water-soluble preparation obtained in the present invention has good solubility in water, it is dissolved in an aqueous medium such as water as described above to form a physiologically active substance-solubilized aqueous solution. It can also be used as a preparation or cosmetic, or can be directly mixed with general foods or feeds.
- the water-solubilized preparation of the present invention is a food such as a general food, a functional nutrition food, a food for specified health use, a nutritional supplement, a nutritional supplement, and a beverage; a pharmaceutical such as a therapeutic drug, a preventive drug, and an animal drug; Can be used for cosmetics, feed, etc.
- MCT
- Example 7 1.5 g of the bioactive substance-containing water-soluble preparation obtained in Examples 1 to 6 and the bioactive substance-containing composition obtained in Comparative Examples 1 to 4, respectively, were added to 100 mL of distilled water to allow uniform diffusion. Thus, a physiologically active substance-solubilized aqueous solution or a physiologically active substance-containing composition aqueous solution was obtained. A small amount of citric acid was added to the physiologically active substance solubilized aqueous solution or the physiologically active substance-containing composition aqueous solution to adjust the pH to 2.9 to obtain an acid treatment solution.
- the particle size distribution of the obtained acid treatment liquid was measured with a dynamic light scattering type particle size distribution apparatus (manufactured by Horiba, Ltd .; trade name: LB-550). The analysis results are shown in Table 1. Moreover, this acid treatment liquid was heated until the internal temperature reached 95 ° C. to obtain an acid / heat treatment liquid. Similarly, the particle size distribution of the obtained acid / heat treatment liquid was measured with a dynamic light scattering type particle size distribution apparatus (manufactured by Horiba, Ltd .; trade name LB-550). The analysis results are shown in Table 1.
- MCT 70% by
- MCT 70% by weight
- Example 12 1.11 g of the physiologically active substance-containing water-soluble preparations obtained in Examples 8 to 11 and the physiologically active substance-containing composition obtained in Comparative Example 5 were respectively added to 100 mL of distilled water and uniformly diffused for physiological activity. A substance-solubilized aqueous solution or a physiologically active substance-containing composition aqueous solution was obtained. A small amount of citric acid was added to the physiologically active substance solubilized aqueous solution or the physiologically active substance-containing composition aqueous solution to adjust the pH to 2.9 to obtain an acid treatment solution.
- the particle size distribution of the obtained acid treatment liquid was measured with a dynamic light scattering type particle size distribution apparatus (manufactured by Horiba, Ltd .; trade name: LB-550). The analysis results are shown in Table 2. Further, this acid treatment liquid was heated until the internal temperature reached 95 ° C. to obtain an acid / heat treatment liquid. Similarly, the particle size distribution of the obtained acid / heat treatment liquid was measured with a dynamic light scattering type particle size distribution apparatus (manufactured by Horiba, Ltd .; trade name LB-550). The analysis results are shown in Table 2.
- Example 14> 2.8 parts by weight of MCT was added to 1 part by weight of the chrysanthemum ethanol extract obtained in Production Example 1 to obtain an oil and fat containing chrysanthemum ethanol extract.
- Example 15 2.8 parts by weight of MCT was added to 1 part by weight of the chrysanthemum ethanol extract obtained in Production Example 1 to obtain an oil and fat containing chrysanthemum ethanol extract.
- surfactant (C) diglycerin monooleate
- Example 16> 2.8 parts by weight of MCT was added to 1 part by weight of the chrysanthemum ethanol extract obtained in Production Example 1 to obtain an oil and fat containing chrysanthemum ethanol extract.
- Example 17 2.8 parts by weight of MCT was added to 1 part by weight of the chrysanthemum ethanol extract obtained in Production Example 1 to obtain an oil and fat containing chrysanthemum ethanol extract.
- Example 18 2.8 parts by weight of MCT was added to 1 part by weight of the chrysanthemum ethanol extract obtained in Production Example 1 to obtain an oil and fat containing chrysanthemum ethanol extract.
- surfactant (C) as diglycerin monooleate (
- Example 19 3.3 g of the physiologically active substance-containing water-soluble preparation obtained in Examples 14 and 15 and 5.0 g of the physiologically active substance-containing water-soluble preparation obtained in Examples 16 to 18 were added to 100 mL of distilled water, A physiologically active substance-solubilized aqueous solution was obtained by uniform diffusion. A small amount of citric acid was added to this physiologically active substance solubilized aqueous solution to adjust the pH to 2.9, and then heating was performed until the internal temperature reached 95 ° C. to obtain an acid / heat treatment solution. The particle size distribution of the obtained acid / heat treatment liquid was measured with a dynamic light scattering type particle size distribution apparatus (manufactured by Horiba, Ltd .; trade name LB-550). The analysis results are shown in Table 4.
- Example 20> 2.8 parts by weight of MCT was added to 1 part by weight of the chrysanthemum ethanol extract obtained in Production Example 1 to obtain an oil and fat containing chrysanthemum ethanol extract.
- a stirrer manufactured by AS ONE; trade name Tornado PM202
- Example 21 2.8 parts by weight of MCT was added to 1 part by weight of the chrysanthemum ethanol extract obtained in Production Example 1 to obtain an oil and fat containing chrysanthemum ethanol extract.
- a stirrer manufactured by AS ONE; trade name Tornado PM202
- Example 22 4.0 g of the physiologically active substance-containing water-soluble preparation obtained in Examples 20 and 21 was added to 100 mL of distilled water and uniformly dispersed to obtain a physiologically active substance-solubilized aqueous solution. This physiologically active substance-solubilized aqueous solution was heated until the internal temperature reached 95 ° C. to obtain a heat treatment solution. The particle size distribution of the heat treatment liquid was measured with a dynamic light scattering particle size distribution apparatus (manufactured by Horiba, Ltd .; trade name LB-550). The analysis results are shown in Table 5.
- Example 23> (Beverage Evaluation 1) Using the physiologically active substance-containing water-soluble preparations of Examples 8 and 9, simulated beverages were prepared with the following formulations, respectively, and heated until the internal temperature reached 95 ° C. and sterilized. None of the obtained simulated beverages were clear without any oil ring caused by heating.
- Bioactive substance-containing water-soluble preparation 1.05 parts by weight Sucrose 4.71 parts by weight Water 94.24 parts by weight Citric acid Adjusted to pH 2.9 ⁇ Example 24> (Beverage evaluation 2) Using the physiologically active substance-containing water-soluble preparations of Examples 20 and 21, simulated beverages were prepared with the following formulations, respectively, and heated until the internal temperature reached 95 ° C. and sterilized. None of the obtained simulated beverages were clear without any oil ring caused by heating.
- Bioactive substance-containing water-soluble preparation 1.05 parts by weight Sucrose 4.71 parts by weight Water 94.24 parts by weight Adjust to citric acid pH 2.9 ⁇ Example 25>
- Example 27 2.8 parts by weight of MCT was added to 1 part by weight of the chrysanthemum ethanol extract obtained in Production Example 1 to obtain an oil and fat containing chrysanthemum ethanol extract.
- polyglycerin fatty acid ester B
- decaglycerin monolaurate manufactured by Riken Vitamin Co., Ltd
- the obtained physiologically active substance-containing water-solubilized preparation 4.0 g was added to 100 mL of distilled water and uniformly diffused to obtain a physiologically active substance-solubilized aqueous solution.
- a small amount of citric acid was added to the physiologically active substance solubilized aqueous solution to adjust the pH to 2.9, and then heating was performed until the internal temperature reached 95 ° C. to obtain an acid / heat treatment solution.
- the particle size distribution immediately after preparation of the obtained acid / heat treatment liquid was measured with a dynamic light scattering particle size distribution apparatus (manufactured by Horiba, Ltd .; trade name LB-550). The analysis results are shown in Table 7.
- Example 28> 2.8 parts by weight of MCT was added to 1 part by weight of the chrysanthemum ethanol extract obtained in Production Example 1 to obtain an oil and fat containing chrysanthemum ethanol extract.
- polyglycerin fatty acid ester B
- decaglycerin monolaurate manufactured by Riken Vitamin Co., Ltd
- the obtained physiologically active substance-containing water-solubilized preparation 4.0 g was added to 100 mL of distilled water and uniformly diffused to obtain a physiologically active substance-solubilized aqueous solution.
- a small amount of citric acid was added to this physiologically active substance solubilized aqueous solution to adjust the pH to 2.9, and then heating was performed until the internal temperature reached 95 ° C. to obtain an acid / heat treatment solution.
- the particle size distribution immediately after preparation of the obtained acid / heat treatment liquid was measured with a dynamic light scattering particle size distribution apparatus (manufactured by Horiba, Ltd .; trade name LB-550). The analysis results are shown in Table 7 above.
- Example 29> 2.8 parts by weight of MCT was added to 1 part by weight of the chrysanthemum ethanol extract obtained in Production Example 1 to obtain an oil and fat containing chrysanthemum ethanol extract.
- the obtained physiologically active substance-containing water-solubilized preparation 4.0 g was added to 100 mL of distilled water and uniformly diffused to obtain a physiologically active substance-solubilized aqueous solution.
- a small amount of citric acid was added to this physiologically active substance solubilized aqueous solution to adjust the pH to 2.9, and then heating was performed until the internal temperature reached 95 ° C. to obtain an acid / heat treatment solution.
- the particle size distribution immediately after preparation of the obtained acid / heat treatment liquid was measured with a dynamic light scattering particle size distribution apparatus (manufactured by Horiba, Ltd .; trade name LB-550). The analysis results are shown in Table 7 above.
- Example 30 The viscosities at various temperatures of the physiologically active substance-containing water-soluble preparations prepared in Examples 8 and 25 to 27 and 29 were measured using a B-type viscometer (MODEL: BL) manufactured by Tokimec Co., Ltd. The results are summarized in Table 8.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
生理活性物質と油脂を含有する油性成分(A)として、甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草エタノール抽出物=30重量%)20重量部、ポリグリセリン脂肪酸エステル(B)として、デカグリセリンモノミリスチン酸エステル(三菱化学フーズ株式会社製;商品名M-7D、HLB=15)74重量部、界面活性剤(C)として、ペンタグリセリントリオレイン酸エステル(太陽化学株式会社製;商品名サンソフト A-173E、HLB=7.0)6重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有水溶化製剤を得た。
生理活性物質と油脂を含有する油性成分(A)として、甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草エタノール抽出物=30重量%)20重量部、ポリグリセリン脂肪酸エステル(B)として、デカグリセリンモノミリスチン酸エステル(三菱化学フーズ株式会社製;商品名M-7D、HLB=15)74重量部、界面活性剤(C)として、ジグリセリンモノオレイン酸エステル(理研ビタミン株式会社製;商品名DO-100V、HLB=7.4)6重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有水溶化製剤を得た。
生理活性物質と油脂を含有する油性成分(A)として、甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草エタノール抽出物=30重量%)20重量部、ポリグリセリン脂肪酸エステル(B)として、デカグリセリンモノミリスチン酸エステル(三菱化学フーズ株式会社製;商品名M-7D、HLB=15)74重量部、界面活性剤(C)として、ジグリセリンモノオレイン酸エステル(理研ビタミン株式会社製;商品名DO-100V、HLB=7.4)6重量部、さらにエタノール500重量部を、室温下、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合した。得られた混合液を減圧濃縮してエタノール含有量が12.1重量%になるまでエタノールを留去し、生理活性物質含有水溶化製剤を得た。
生理活性物質と油脂を含有する油性成分(A)として、甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草エタノール抽出物=30重量%)20重量部、ポリグリセリン脂肪酸エステル(B)として、デカグリセリンモノミリスチン酸エステル(三菱化学フーズ株式会社製;商品名M-7D、HLB=15)74重量部、界面活性剤(C)として、テトラグリセリンモノラウリン酸エステル(阪本薬品工業株式会社製;商品名SYグリスター ML-310、HLB=10.3)6重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有水溶化製剤を得た。
生理活性物質と油脂を含有する油性成分(A)として、甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草エタノール抽出物=30重量%)20重量部、ポリグリセリン脂肪酸エステル(B)として、デカグリセリンモノミリスチン酸エステル(三菱化学フーズ株式会社製;商品名M-7D、HLB=15)74重量部、界面活性剤(C)として、テトラグリセリンモノステアリン酸エステル(阪本薬品工業株式会社製;商品名SYグリスター MS-3S、HLB=8.4)6重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有水溶化製剤を得た。
生理活性物質と油脂を含有する油性成分(A)として、甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草エタノール抽出物=30重量%)20重量部、ポリグリセリン脂肪酸エステル(B)として、デカグリセリンモノミリスチン酸エステル(三菱化学フーズ株式会社製;商品名M-7D、HLB=15)74重量部、界面活性剤(C)として、ヘキサグリセリンモノオレイン酸エステル(阪本薬品工業株式会社製;商品名SYグリスター MO-5S、HLB=11.6)6重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有水溶化製剤を得た。
甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草エタノール抽出物=30重量%)20重量部、デカグリセリンモノミリスチン酸エステル(三菱化学フーズ株式会社製;商品名M-7D、HLB=15)74重量部、デカグリセリンモノステアリン酸エステル(阪本薬品工業株式会社製;商品名SYグリスター MM-750、HLB=15.5)6重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有組成物を得た。
甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草エタノール抽出物=30重量%)20重量部、デカグリセリンモノミリスチン酸エステル(三菱化学フーズ株式会社製;商品名M-7D、HLB=15)74重量部、デカグリセリンモノステアリン酸エステル(太陽化学株式会社製;商品名サンソフト Q-18S、HLB=12.0)6重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有組成物を得た。
甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草エタノール抽出物=30重量%)20重量部、ジグリセリンモノ・ジオレイン酸エステル(太陽化学株式会社製;商品名サンソフト Q-17B、HLB=6.5)6重量部、ジグリセリンモノオレイン酸エステルジグリセリンモノ・ジオレイン酸エステル(太陽化学株式会社製;商品名サンソフト Q-17B、HLB=6.5)6重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有組成物を得た。
甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草エタノール抽出物=30重量%)20重量部、ヘキサグリセリンモノオレイン酸エステル(阪本薬品工業株式会社製;商品名SYグリスター MO-5S、HLB=11.6)74重量部、ジグリセリンモノオレイン酸エステル(理研ビタミン株式会社製;商品名DO-100V、HLB=7.4)6重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有組成物を得た。
実施例1~6で得られた生理活性物質含有水溶化製剤と比較例1~4で得られた生理活性物質含有組成物、それぞれ1.5gを、蒸留水100mL中に添加し、均一拡散させて生理活性物質可溶化水溶液又は生理活性物質含有組成物水溶液を得た。この生理活性物質可溶化水溶液又は生理活性物質含有組成物水溶液中にクエン酸を少量添加してpHを2.9に調整し、酸処理液とした。得られた酸処理液の粒度分布を動的光散乱式粒径分布装置(株式会社堀場製作所製;商品名LB-550)で測定した。分析結果を表1に示す。また、この酸処理液を内温が95℃に達するまで加熱し、酸・熱処理液とした。同様に、得られた酸・熱処理液の粒度分布を動的光散乱式粒径分布装置(株式会社堀場製作所製;商品名LB-550)で測定した。分析結果を表1に示す。
生理活性物質と油脂を含有する油性成分(A)として、甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草エタノール抽出物=30重量%)27重量部、ポリグリセリン脂肪酸エステル(B)として、デカグリセリンモノミリスチン酸エステル(三菱化学フーズ株式会社製;商品名M-7D、HLB=15)67重量部、界面活性剤(C)として、ジグリセリンモノオレイン酸エステル(理研ビタミン株式会社製;商品名DO-100V、HLB=7.4)6重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有水溶化製剤を得た。
生理活性物質と油脂を含有する油性成分(A)として、甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草エタノール抽出物=30重量%)27重量部、ポリグリセリン脂肪酸エステル(B)として、デカグリセリンモノミリスチン酸エステル(三菱化学フーズ株式会社製;商品名M-7D、HLB=15)67重量部、界面活性剤(C)として、テトラグリセリンモノラウリン酸エステル(阪本薬品工業株式会社製;商品名SYグリスター ML-310、HLB=10.3)6重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有水溶化製剤を得た。
生理活性物質と油脂を含有する油性成分(A)として、甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草エタノール抽出物=30重量%)27重量部、ポリグリセリン脂肪酸エステル(B)として、デカグリセリンモノミリスチン酸エステル(三菱化学フーズ株式会社製;商品名M-7D、HLB=15)67重量部、界面活性剤(C)として、ヘキサグリセリンモノオレイン酸エステル(阪本薬品工業株式会社製;商品名SYグリスター MO-5S、HLB=11.6)6重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有水溶化製剤を得た。
生理活性物質と油脂を含有する油性成分(A)として、甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草エタノール抽出物=30重量%)27重量部、ポリグリセリン脂肪酸エステル(B)として、デカグリセリンモノミリスチン酸エステル(三菱化学フーズ株式会社製;商品名M-7D、HLB=15)67重量部、界面活性剤(C)として、ヘキサグリセリンジステアリン酸エステル(阪本薬品工業株式会社製;商品名SYグリスター MS-5S、HLB=11.6)6重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有水溶化製剤を得た。
甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名グラボノイド、MCT=70重量%、甘草エタノール抽出物=30重量%)27重量部、ヘキサグリセリンモノオレイン酸エステル(阪本薬品工業株式会社製;商品名SYグリスター MO-5S、HLB=11.6)67重量部、ジグリセリンモノオレイン酸エステル(理研ビタミン株式会社製;商品名DO-100V、HLB=7.4)6重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有組成物を得た。
実施例8~11で得られた生理活性物質含有水溶化製剤と比較例5で得られた生理活性物質含有組成物それぞれ1.11gを、蒸留水100mL中に添加し、均一拡散させて生理活性物質可溶化水溶液又は生理活性物質含有組成物水溶液を得た。この生理活性物質可溶化水溶液又は生理活性物質含有組成物水溶液中にクエン酸を少量添加してpHを2.9に調整し、酸処理液とした。得られた酸処理液の粒度分布を動的光散乱式粒径分布装置(株式会社堀場製作所製;商品名LB-550)で測定した。分析結果を表2に示す。また、この酸処理液を内温が95℃に達するまで加熱して、酸・熱処理液とした。同様に、得られた酸・熱処理液の粒度分布を動的光散乱式粒径分布装置(株式会社堀場製作所製;商品名LB-550)で測定した。分析結果を表2に示す。
生理活性物質と油脂を含有する油性成分(A)として、甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草エタノール抽出物=30重量%)27重量部に対し、ポリグリセリン脂肪酸エステル(B)として、デカグリセリンモノミリスチン酸エステル(三菱化学フーズ株式会社製;商品名M-7D、HLB=15)と、界面活性剤(C)として、ジグリセリンモノオレイン酸エステル(理研ビタミン株式会社製;商品名DO-100V、HLB=7.4)を、それぞれ表3に示す割合で使用し、これら3成分を50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有水溶化製剤を得た。
甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草エタノール抽出物=30重量%)27重量部、デカグリセリンモノミリスチン酸エステル(三菱化学フーズ株式会社製;商品名M-7D、HLB=15)73重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有組成物を得た。
甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草エタノール抽出物=30重量%)27重量部、デカグリセリンモノミリスチン酸エステル(三菱化学フーズ株式会社製;商品名M-7D、HLB=15)6重量部、ジグリセリンモノオレイン酸エステル(理研ビタミン株式会社製;商品名DO-100V、HLB=7.4)67重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有組成物を得た。
菊の頭花を50℃に加温した93%エタノール水溶液に3時間浸潤し、抽出を行なった。その後、ろ過により残渣を除去して抽出液を取得し、得られた抽出液を減圧濃縮して溶媒を除去し、菊花エタノール抽出物を得た。
製造例1で得られた菊花エタノール抽出物1重量部にMCTを2.8重量部添加し、菊花エタノール抽出物含有油脂とした。
製造例1で得られた菊花エタノール抽出物1重量部にMCTを2.8重量部添加し、菊花エタノール抽出物含有油脂とした。
製造例1で得られた菊花エタノール抽出物1重量部にMCTを2.8重量部添加し、菊花エタノール抽出物含有油脂とした。
製造例1で得られた菊花エタノール抽出物1重量部にMCTを2.8重量部添加し、菊花エタノール抽出物含有油脂とした。
製造例1で得られた菊花エタノール抽出物1重量部にMCTを2.8重量部添加し、菊花エタノール抽出物含有油脂とした。
実施例14、15で得られた生理活性物質含有水溶化製剤3.3g、実施例16~18で得られた生理活性物質含有水溶化製剤5.0gを、それぞれ蒸留水100mL中に添加し、均一拡散させて生理活性物質可溶化水溶液を得た。この生理活性物質可溶化水溶液中にクエン酸を少量添加してpHを2.9に調整した後、内温が95℃に達するまで加熱を行って酸・熱処理液とした。得られた酸・熱処理液の粒度分布を動的光散乱式粒径分布装置(株式会社堀場製作所製;商品名LB-550)で測定した。分析結果を表4に示す。
製造例1で得られた菊花エタノール抽出物1重量部にMCTを2.8重量部添加し、菊花エタノール抽出物含有油脂とした。
製造例1で得られた菊花エタノール抽出物1重量部にMCTを2.8重量部添加し、菊花エタノール抽出物含有油脂とした。
実施例20、21で得られた生理活性物質含有水溶化製剤4.0gを、蒸留水100mL中に添加し、均一拡散させて生理活性物質可溶化水溶液を得た。この生理活性物質可溶化水溶液を、内温が95℃に達するまで加熱し、熱処理液とした。熱処理液の粒度分布を動的光散乱式粒径分布装置(株式会社堀場製作所製;商品名LB-550)で測定した。分析結果を表5に示す。
(飲料評価1)
実施例8、9の生理活性物質含有水溶化製剤を用い、以下の配合でそれぞれ模擬飲料を作成し、内温が95℃に達するまで加熱を行い、殺菌処理した。得られた模擬飲料は、いずれも加熱によるオイルリングも生じず、澄明な状態であった。
スクロース 4.71重量部
水 94.24重量部
クエン酸 pH2.9に調整
<実施例24>
(飲料評価2)
実施例20、21の生理活性物質含有水溶化製剤を用い、以下の配合でそれぞれ模擬飲料を作成し、内温が95℃に達するまで加熱を行い、殺菌処理した。得られた模擬飲料は、いずれも加熱によるオイルリングも生じず、澄明な状態であった。
スクロース 4.71重量部
水 94.24重量部
クエン酸 pH2.9に調整
<実施例25>
生理活性物質と油脂を含有する油性成分(A)として、甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草油性抽出物=30重量%)27重量部、ポリグリセリン脂肪酸エステル(B)として、デカグリセリンモノミリスチン酸エステル(三菱化学フーズ株式会社製;商品名M-7D、HLB=15)62重量部、界面活性剤(C)として、ジグリセリンモノオレイン酸エステル(理研ビタミン株式会社製;商品名DO-100V、HLB=7.4)6重量部、及び蒸留水5重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有水溶化製剤を得た。
得られた生理活性物質含有水溶化製剤1.11gを、蒸留水100mL中に添加し、均一拡散させて生理活性物質可溶化水溶液を得た。この生理活性物質可溶化水溶液中にクエン酸を少量添加してpHを2.9に調整した後、内温が95℃に達するまで加熱を行って酸・熱処理液とした。得られた酸・熱処理液の作成直後と、25℃で19日保存したあとの粒度分布を動的光散乱式粒径分布装置(株式会社堀場製作所製;商品名LB-550)で測定した。分析結果を表6に示す。
生理活性物質と油脂を含有する油性成分(A)として、甘草エタノール抽出物含有油脂(株式会社カネカ製;商品名「グラボノイド」、MCT=70重量%、甘草油性抽出物=30重量%)27重量部、ポリグリセリン脂肪酸エステル(B)として、デカグリセリンモノミリスチン酸エステル(三菱化学フーズ株式会社製;商品名M-7D、HLB=15)57重量部、界面活性剤(C)として、ジグリセリンモノオレイン酸エステル(理研ビタミン株式会社製;商品名DO-100V、HLB=7.4)6重量部、及び蒸留水10重量部を、それぞれ50℃に加温し、撹拌機(AS ONE社製;商品名トルネード PM202)を用いて常圧下200rpmで均一混合して生理活性物質含有水溶化製剤を得た。
得られた生理活性物質含有水溶化製剤1.11gを、蒸留水100mL中に添加し、均一拡散させて生理活性物質可溶化水溶液を得た。この生理活性物質可溶化水溶液中にクエン酸を少量添加してpHを2.9に調整した後、内温が95℃に達するまで加熱を行って酸・熱処理液とした。得られた酸・熱処理液の作成直後と、25℃で19日保存したあとの粒度分布を動的光散乱式粒径分布装置(株式会社堀場製作所製;商品名LB-550)で測定した。分析結果を前記表6に示す。
製造例1で得られた菊花エタノール抽出物1重量部にMCTを2.8重量部添加し、菊花エタノール抽出物含有油脂とした。
製造例1で得られた菊花エタノール抽出物1重量部にMCTを2.8重量部添加し、菊花エタノール抽出物含有油脂とした。
製造例1で得られた菊花エタノール抽出物1重量部にMCTを2.8重量部添加し、菊花エタノール抽出物含有油脂とした。
実施例8、及び25~27、29で調製した生理活性物質含有水溶化製剤の各種温度における粘度を(株)トキメック社製B型粘度計(MODEL:BL)を用いてそれぞれ測定した。その結果を表8にまとめた。
Claims (13)
- 生理活性物質と油脂を含有する油性成分(A)を1~50重量%、HLB値が12.5以上のポリグリセリン脂肪酸エステル(B)を10~98重量%、及びHLB値が7~11.8の界面活性剤(C)を1~40重量%含有する生理活性物質含有水溶化製剤。
- HLB値が12.5以上のポリグリセリン脂肪酸エステル(B)が、平均重合度10のポリグリセリンと炭素数12~16の脂肪酸で構成されるポリグリセリンモノ脂肪酸エステルである、請求項1記載の生理活性物質含有水溶化製剤。
- HLB値が7~11.8の界面活性剤(C)が、平均重合度2~6のポリグリセリンと炭素数12~18の脂肪酸で構成されるポリグリセリン脂肪酸エステルである、請求項1又は2記載の生理活性物質含有水溶化製剤。
- 生理活性物質が植物抽出物、脂溶性ビタミン類又はカロチノイド類である、請求項1~3のいずれか1項記載の生理活性物質含有水溶化製剤。
- 植物抽出物が、甘草及び菊花からなる群より選択される1種以上の植物の抽出物である、請求項4記載の生理活性物質含有水溶化製剤。
- さらに、水及び/又はアルコール類を含有してなる請求項1~5いずれか1項記載の生理活性物質含有水溶化製剤。
- アルコール類がエタノールである請求項6記載の生理活性物質含有水溶化製剤。
- 生理活性物質含有水溶化製剤中の水及びアルコール類の含有量の合計が12重量%以下である請求項6又は7記載の生理活性物質含有水溶化製剤。
- 請求項1~8いずれか1項記載の生理活性物質含有水溶化製剤を水又は水溶液に添加して得られる生理活性物質可溶化水溶液。
- 生理活性物質と油脂を含有する油性成分(A)を1~50重量%、HLB値が12.5以上のポリグリセリン脂肪酸エステル(B)を10~98重量%、及びHLB値が7~11.8の界面活性剤(C)を1~40重量%含有する生理活性物質含有水溶化製剤を水又は水溶液に添加した後に、加熱処理及び/又は酸処理することを特徴とする、生理活性物質可溶化水溶液の製造方法。
- 加熱処理が、生理活性物質含有水溶化製剤と水又は水溶液の混合物を80℃以上に加熱することである請求項10に記載の生理活性物質可溶化水溶液の製造方法。
- 酸処理が、生理活性物質含有水溶化製剤と水又は水溶液の混合物のpHを4.0以下に調整することである請求項10又は11に記載の生理活性物質可溶化水溶液の製造方法。
- 生理活性物質含有水溶化製剤として水及び/又はアルコール類をさらに含有する水溶化製剤を使用する、請求項10~12のいずれか1項記載の生理活性物質可溶化水溶液の製造方法。
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012800072935A CN103338748A (zh) | 2011-02-01 | 2012-01-31 | 含生理活性物质的水溶化制剂及其制造方法 |
| US13/982,841 US9919017B2 (en) | 2011-02-01 | 2012-01-31 | Biologically active substance-containing water-solubilizing preparation and method for producing the same |
| MX2013008090A MX358308B (es) | 2011-02-01 | 2012-01-31 | Preparacion solubilizante en agua que contiene sustancia biologicamente activa y metodo para producirla. |
| JP2012555894A JP6047404B2 (ja) | 2011-02-01 | 2012-01-31 | 生理活性物質含有水溶化製剤、及びその製法 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011-019892 | 2011-02-01 | ||
| JP2011019892 | 2011-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2012105551A1 true WO2012105551A1 (ja) | 2012-08-09 |
Family
ID=46602763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2012/052133 Ceased WO2012105551A1 (ja) | 2011-02-01 | 2012-01-31 | 生理活性物質含有水溶化製剤、及びその製法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9919017B2 (ja) |
| JP (1) | JP6047404B2 (ja) |
| CN (1) | CN103338748A (ja) |
| MX (1) | MX358308B (ja) |
| WO (1) | WO2012105551A1 (ja) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014025039A (ja) * | 2012-07-30 | 2014-02-06 | Riken Vitamin Co Ltd | 食品用油溶性色素製剤 |
| JP2016516776A (ja) * | 2013-04-09 | 2016-06-09 | ボストン バイオメディカル, インコーポレイテッド | がんの処置に使用するための2−アセチルナフト[2,3−b]フラン−4,9−ジオン |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10799479B2 (en) | 2015-04-10 | 2020-10-13 | Bioresponse, L.L.C. | Self-emulsifying formulations of DIM-related indoles |
| US11471426B2 (en) | 2019-10-16 | 2022-10-18 | American River Nutrition, Llc | Compositions comprising quinone and/or quinol and methods of preparations and use thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001081039A (ja) * | 1999-09-13 | 2001-03-27 | Nippon Zoki Pharmaceut Co Ltd | タキキニン拮抗剤 |
| JP2004196781A (ja) * | 2002-12-04 | 2004-07-15 | Nof Corp | コエンザイムq10を含有する水溶性組成物 |
| JP2004261005A (ja) * | 2003-01-17 | 2004-09-24 | Taiyo Kagaku Co Ltd | ユビデカレノン製剤 |
| JP2005143317A (ja) * | 2003-11-11 | 2005-06-09 | Tama Seikagaku Kk | 植物ステロールを含有する水分散型製剤 |
| JP2005343799A (ja) * | 2004-05-31 | 2005-12-15 | Nisshin Oillio Group Ltd | 水分散性植物ステロース製剤と油脂含有水分散性植物ステロール製剤 |
| WO2007097412A1 (ja) * | 2006-02-24 | 2007-08-30 | Kaneka Corporation | 甘草ポリフェノール含有水中油型乳化組成物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2794433B2 (ja) | 1989-02-02 | 1998-09-03 | 丸善製薬株式会社 | 甘草疎水性フラボノイド製剤 |
| US5990180A (en) | 1995-03-29 | 1999-11-23 | Mitsubishi Chemical Corporation | Aqueous composition containing solubilized or dispersed oil-soluble substance |
| JP4582823B2 (ja) | 1995-03-29 | 2010-11-17 | 三菱化学株式会社 | 油溶性物質が可溶化ないし分散されてなる水性組成物 |
| JP3528382B2 (ja) | 1995-12-20 | 2004-05-17 | 日本油脂株式会社 | 油脂可溶化組成物、その製造方法およびそれを含有する飲食品 |
| JP3653884B2 (ja) | 1996-09-13 | 2005-06-02 | 日本油脂株式会社 | 油溶性物質可溶化組成物、その製法及び飲食品 |
| JP2002291442A (ja) * | 2001-04-02 | 2002-10-08 | Nof Corp | 植物ステロール含有水溶性組成物、製造方法および用途 |
| JP3935346B2 (ja) | 2001-12-12 | 2007-06-20 | 三井農林株式会社 | 水系対象物への甘草油性抽出物可溶化方法 |
| WO2003084556A1 (en) | 2002-04-04 | 2003-10-16 | Kaneka Corporation | Process for producing fat composition containing hydrophobic components of glycyrrhiza |
| JP4304940B2 (ja) * | 2002-08-30 | 2009-07-29 | 有限会社ビオメディクス | 水分散用プロポリス抽出物含有組成物および飲料 |
| KR101061679B1 (ko) | 2002-12-04 | 2011-09-02 | 닛신 파마 가부시키가이샤 | 코엔자임 q10 을 함유하는 수용성 조성물 |
| US8758743B2 (en) | 2003-01-17 | 2014-06-24 | Taiyo Kagaku Co., Ltd. | Compositions containing coenzyme Q10 |
| TW200808333A (en) | 2006-04-17 | 2008-02-16 | Kaneka Corp | Licorice polyphenol preparation |
| WO2008004509A1 (fr) | 2006-07-03 | 2008-01-10 | The Nisshin Oillio Group, Ltd. | Composition huileuse contenant du squalène et émulsion eau dans l'huile contenant du squalène |
| US20080131515A1 (en) * | 2006-12-01 | 2008-06-05 | Fujifilm Corporation | Emulsion composition, and foods and cosmetics containing the emulsion composition |
-
2012
- 2012-01-31 US US13/982,841 patent/US9919017B2/en not_active Expired - Fee Related
- 2012-01-31 JP JP2012555894A patent/JP6047404B2/ja active Active
- 2012-01-31 WO PCT/JP2012/052133 patent/WO2012105551A1/ja not_active Ceased
- 2012-01-31 MX MX2013008090A patent/MX358308B/es active IP Right Grant
- 2012-01-31 CN CN2012800072935A patent/CN103338748A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001081039A (ja) * | 1999-09-13 | 2001-03-27 | Nippon Zoki Pharmaceut Co Ltd | タキキニン拮抗剤 |
| JP2004196781A (ja) * | 2002-12-04 | 2004-07-15 | Nof Corp | コエンザイムq10を含有する水溶性組成物 |
| JP2004261005A (ja) * | 2003-01-17 | 2004-09-24 | Taiyo Kagaku Co Ltd | ユビデカレノン製剤 |
| JP2005143317A (ja) * | 2003-11-11 | 2005-06-09 | Tama Seikagaku Kk | 植物ステロールを含有する水分散型製剤 |
| JP2005343799A (ja) * | 2004-05-31 | 2005-12-15 | Nisshin Oillio Group Ltd | 水分散性植物ステロース製剤と油脂含有水分散性植物ステロール製剤 |
| WO2007097412A1 (ja) * | 2006-02-24 | 2007-08-30 | Kaneka Corporation | 甘草ポリフェノール含有水中油型乳化組成物 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014025039A (ja) * | 2012-07-30 | 2014-02-06 | Riken Vitamin Co Ltd | 食品用油溶性色素製剤 |
| JP2016516776A (ja) * | 2013-04-09 | 2016-06-09 | ボストン バイオメディカル, インコーポレイテッド | がんの処置に使用するための2−アセチルナフト[2,3−b]フラン−4,9−ジオン |
Also Published As
| Publication number | Publication date |
|---|---|
| MX358308B (es) | 2018-08-14 |
| MX2013008090A (es) | 2013-10-03 |
| US9919017B2 (en) | 2018-03-20 |
| JP6047404B2 (ja) | 2016-12-21 |
| US20130309338A1 (en) | 2013-11-21 |
| JPWO2012105551A1 (ja) | 2014-07-03 |
| CN103338748A (zh) | 2013-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101321472B (zh) | 用于食品和饮料制品中的微乳剂 | |
| JP5070203B2 (ja) | 甘草ポリフェノール製剤 | |
| JPWO2007097412A1 (ja) | 甘草ポリフェノール含有水中油型乳化組成物 | |
| JP4685355B2 (ja) | 甘草疎水性成分含有油脂組成物の製造方法 | |
| US11136417B2 (en) | Low molecular gum ghatti | |
| JP6964660B2 (ja) | 酸化防止剤分散物 | |
| JP5192356B2 (ja) | 飲料用乳化組成物 | |
| JP2551755B2 (ja) | 可溶化液の製造法 | |
| JP4910927B2 (ja) | アスタキサンチン含有乳化物、および製造方法 | |
| US20180317523A1 (en) | Nanoparticles, nanoemulsions and their formation with mixing chamber micronization | |
| JP6047404B2 (ja) | 生理活性物質含有水溶化製剤、及びその製法 | |
| JP5288407B2 (ja) | 油溶性物質のo/w型乳化組成物 | |
| JP5738721B2 (ja) | ソフトカプセル製剤及びその製造方法 | |
| WO2013031949A1 (ja) | ソフトカプセル製剤、ソフトカプセル製剤用組成物、及びソフトカプセル製剤の製造方法 | |
| JP5196833B2 (ja) | 機能性食品素材とその製造方法 | |
| WO2006134970A1 (ja) | コエンザイムq10含有水溶性組成物及びその製法 | |
| WO2007046333A1 (ja) | 乳化剤およびそれを用いて調製される乳化組成物 | |
| JP7032260B2 (ja) | 油性組成物 | |
| JP6941481B2 (ja) | 植物抽出物を含む水溶化粉末 | |
| JP2551755C (ja) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12741899 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2012555894 Country of ref document: JP Kind code of ref document: A |
|
| WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/008090 Country of ref document: MX |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 13982841 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12741899 Country of ref document: EP Kind code of ref document: A1 |







